statement
領展宣布從英康保險手中收購新加坡東福坊50.1%的股權,總代價為2.36億新加坡元,這是該基金自2022年以來的首次收購。
A statement by 瑞銀. Statements are as reported by the cited publishers — not verified by DecisionGateway.
領展(00823.HK)昨晚宣布從英康保險(Income Insurance)手中收購新加坡東福坊(Eastpoint Mall)50.1%的股權,總代價為2.36億新加坡元;這是該基金自2022年以來的首次收購。
Discussion
Related claims
領展資產管理宣布向英康保險收購新加坡東福坊50.1%權益,代價為2.395億新加坡元,折合約14.7億港元。領展資產管理 · statement領展房產基金宣布擬以2.395億新加坡元收購新加坡東福坊50.1%權益。領展房產基金 · commitment領展房託將以2.395億坡元(約14.7億港元)向英康保險收購新加坡東福坊(Eastpoint Mall)的50.1%權益。信報 · commitment領展房產基金 announced it plans to acquire 50.1% of Singapore's Eastpoint Mall for S$239.5 million from 英康保險.領展房產基金 · commitment英康保險繼續持有東福坊餘下49.9%權益,領展將成為東福坊的資產管理人及物業管理人。領展資產管理 · statementLink REIT will acquire a 50.1% interest in Eastpoint Mall from Income Insurance for SGD 239.5 million.領展房產基金 · commitment
More claims by 瑞銀
Although divesting Frontage may affect some global synergies in the short term, the transaction can improve Tigermed's business portfolio and capital allocation while supporting further expansion of overseas clinical CRO business, supplementing working capital and raising shareholder returns.predictionTigermed plans to use about 60% of net cash proceeds for overseas clinical CRO expansion and M&A, 20% for daily operations, and the remaining about 20% possibly for dividends or share buybacks.statementIf the transaction completes, Tigermed can divest non-core businesses including overseas laboratories, CMC and genomics to focus more on clinical CRO services.predictionFrontage's laboratory network in the US and Europe is an important platform linking Tigermed to global markets; it supports the strategy of dual IND filings in China and the US and helps Chinese innovative drugmakers expand overseas, so divesting Frontage may affect Tigermed's global footprint and cross-border drug R&D competitiveness to some extent.statementAfter the privatization, Tigermed plans to acquire Frontage's mainland China non-target businesses at a preliminary valuation of about US$205.5 million; target businesses such as bioanalysis and DMPK will be sold to Charles River Laboratories at a preliminary valuation of about US$470 million; founder Li Song and related trusts may acquire the overseas non-target businesses at a preliminary valuation of about US$84.4 million.statement
All claims by 瑞銀